Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 1637.

https://doi.org/10.1182/blood-2019-128265

Published: 2019

Journal Articles

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Fernanda F Engelbrecht, Eliana C Miranda, PhD, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 2938.

https://doi.org/10.1182/blood-2019-129388

Published: 2019

Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Renato Torrescasana Centrone, Isabel Bonafe, Eliana C Miranda, PhD, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD MSc, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Ingrid Luise, MD, Monika Conchon, MD, Natália N Gonçalves, MD, Jaisson Bortolini, MD, Laura Maria Fogliatto, MD PhD, Carmino Antonio Souza, MD PhD, Katia B Pagnano, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 5844.

https://doi.org/10.1182/blood-2019-127530

Published: 2019

Journal Articles

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

Blood (2018) 132 (Supplement 1): 46.

https://doi.org/10.1182/blood-2018-99-113718

Published: 2018

Journal Articles

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

Matheus Sebastian Da Silva, Eliana C Miranda, Marcia Torresan Delamain, MD, Gislaine Oliveira Duarte, MD, Bruna R Vergilio, Ana Beatriz Pascoal Lopes, Jessica CN Vianna, Carmino Antonio De Souza, MD PhD, Erich Vinicius De Paula, MD PhD, Katia B Pagnano, MD

Blood (2018) 132 (Supplement 1): 1749.

https://doi.org/10.1182/blood-2018-99-114036

Published: 2018

Journal Articles

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Katia B Pagnano, MD, Eliana C Miranda, Marcia Torresan Delamain, Gislaine Oliveira Duarte, MD, Bruna Virgilio, Jessica Vianna, Erich Vinicius De Paula, MD PhD, Carmino Antonio De Souza, MD PhD

Blood (2017) 130 (Supplement 1): 1595.

https://doi.org/10.1182/blood.V130.Suppl_1.1595.1595

Published: 2017

Journal Articles

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

Katia B Pagnano, MD, Eliana C Miranda, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Maryanna N Da Silva, Renato Centrone, MD, Monika Conchon, MD, Jaisson Bortolini, MD, Teresa Cristina Bortolheiro, MD, Valquiria Povoa, Luciana Nardinelli, Carmino Antonio De Souza, MD PhD, Israel Bendit, MD PhD

Blood (2017) 130 (Supplement 1): 1596.

https://doi.org/10.1182/blood.V130.Suppl_1.1596.1596

Published: 2017

NARROW

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only